Vivo Capital LLC Lowers Stock Holdings in Abivax SA Sponsored ADR $ABVX

Vivo Capital LLC lessened its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 33.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 239,539 shares of the company’s stock after selling 119,766 shares during the period. Abivax makes up 2.2% of Vivo Capital LLC’s portfolio, making the stock its 14th largest position. Vivo Capital LLC’s holdings in Abivax were worth $26,673,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. lifted its position in Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after acquiring an additional 140 shares during the period. WPG Advisers LLC increased its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the period. Assetmark Inc. increased its holdings in shares of Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after purchasing an additional 260 shares during the period. SmartHarvest Portfolios LLC raised its stake in shares of Abivax by 11.6% during the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock worth $300,000 after purchasing an additional 280 shares during the last quarter. Finally, Personal CFO Solutions LLC raised its stake in shares of Abivax by 10.5% during the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock worth $337,000 after purchasing an additional 288 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Price Performance

Shares of ABVX stock opened at $124.33 on Friday. The business’s fifty day moving average price is $118.48 and its 200 day moving average price is $118.36. Abivax SA Sponsored ADR has a 1-year low of $67.09 and a 1-year high of $148.83. The firm has a market capitalization of $10.85 billion, a PE ratio of -23.86 and a beta of 0.87.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts expect that Abivax SA Sponsored ADR will post -3.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

ABVX has been the subject of several recent research reports. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Oddo Bhf restated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Wedbush raised their target price on shares of Abivax from $90.00 to $110.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. Truist Financial lifted their target price on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Finally, Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and lifted their target price for the company from $108.00 to $158.00 in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $156.50.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.